VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lymphoma Cancer

Ryan Hamner
How a break from the hospital led directly to an encounter with the police.
Ryan Hamner
The story of the "Hear the Heart" Tour.
Ryan Hamner
How a young boy on chemo marked the days until the end of his treatments.
Ryan Hamner
How a clown named Miss Sydney helped so many kids battling cancer.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).
Ryan Hamner
Perspective is important with cancer and remission.
Ryan Hamner
This cancer survivor shares his experience with advancements in cancer treatment.
Ryan Hamner
Thinking back on my friends who fought cancer with me can sometimes be daunting, but I like to look for the silver lining.
Silas Inman
Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable